Enanta Pharmaceuticals (ENTA) EBITDA Margin (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted EBITDA Margin of 69.07% for Q1 2026, down 14.26% on a QoQ basis from 60.45% in Q4 2025, and up 9525.0% year-over-year from 0.72% in Q1 2025.
Enanta Pharmaceuticals (ENTA) EBITDA Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' EBITDA Margin history runs 15 years deep, the most recent figure standing at 69.07% for Q1 2026.
- Quarterly EBITDA Margin rose 9525.0% year-over-year to 69.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 87.24% (up 7116.0% YoY) and the FY2025 annual result came in at 130.65%, up 4927.0% from the prior year.
- EBITDA Margin was 69.07% for Q1 2026 at Enanta Pharmaceuticals, down from 60.45% in the prior quarter.
- Across five years, EBITDA Margin topped out at 60.45% in Q4 2025 and bottomed at 221.7% in Q1 2023.
- A 5-year average of 151.2% and a median of 163.9% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin slumped 6652 bps — and 2026, when it surged 9525 bps.
- Enanta Pharmaceuticals' EBITDA Margin stood at 127.25% in 2022, then plunged by 52 bps to 193.78% in 2023, then advanced by 28 bps to 138.82% in 2024, then soared by 56 bps to 60.45% in 2025, then declined by 14 bps to 69.07% in 2026.
- Business Quant data shows ENTA's EBITDA Margin at 69.07% in Q1 2026, 60.45% in Q4 2025, and 121.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | -69.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.07% |
| Dec 31, 2025 | -60.45% |
| Sep 30, 2025 | -121.56% |
| Jun 30, 2025 | -103.16% |
| Mar 31, 2025 | -164.32% |
| Dec 31, 2024 | -138.82% |
| Sep 30, 2024 | -204.38% |
| Jun 30, 2024 | -134.58% |
| Mar 31, 2024 | -192.13% |
| Dec 31, 2023 | -193.78% |
| Sep 30, 2023 | -163.90% |
| Jun 30, 2023 | -194.33% |
| Mar 31, 2023 | -221.70% |
| Dec 31, 2022 | -127.25% |
| Sep 30, 2022 | -133.13% |
| Jun 30, 2022 | -167.05% |
| Mar 31, 2022 | -180.85% |
| Dec 31, 2021 | -109.99% |
| Sep 30, 2021 | -143.06% |
| Jun 30, 2021 | -156.53% |